Corrigendum to "A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy" [Clinica Chimica Acta 389 (2008)L-6] (DOI:10.1016/j.cca.2007.11.003);A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy

Clinica Chimica Acta

Volumn 389, Issue 1-2, 2008, Pages 1-6

  Sokoll, Lori J ^a   Ellis, William ^b   Lange, Paul ^b   Noteboom, Jennifer ^b   Elliott, Debra J ^a   Deras, Ina L ^c   Blase, Amy ^c   Koo, Seongjoon ^c   Sarno, Mark ^c   Rittenhouse, Harry ^c   Groskopf, Jack ^c   Vessella, Robert L ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Gen Probe Incorporated   (United States)

Author keywords

Molecular urine test; PCA3; Prostate cancer; PSA

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; STATISTICAL SIGNIFICANCE; URINALYSIS;

EID: 38649115353     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.03.052     Document Type: Erratum

References (14)

1. National Cancer Institute, NIH. Available at: http://www.cancer.gov/cancertopics/factsheet/Detection/PSA. Accessed March 29, 2007.
2. Smith R.A., Cokkinides V., and Eyre H.J. Cancer screening in the United States 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 57 (2007) 90-104
3. Reynolds M.A., Kastury K., Groskopf J., Schalken J.A., and Rittenhouse H. Molecular markers for prostate cancer. Cancer Lett 249 (Feb 13 2007) 5-13
4. Bussemakers M.J.G., Van Bokhoven A., et al. DD3: a new prostate-specific gene, highly over-expressed in prostate cancer. Cancer Res 59 (1999) 5975-5979
5. De Kok J.B., Verhaegh G.W., Roelofs R.W., et al. DD3PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695-2698
6. PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8-16
7. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089-1095
8. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver-operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837-845
9. Marks L.S., Fradet Y., Deras I.L., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532-535
10. Tango T. Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med 17 (1998) 891-908
11. Fradet Y., Saad F., Aprikian A., et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64 (2004) 311-316
12. van Gils M.P.M.Q., Hessels D., van Hooij O., et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13 (2007) 939-943
13. Petrovics G., Liu A., Shaheduzzaman S., et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24 (2005) 3847-3852
14. Schmidt U., Fuessel S., Koch R., et al. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 66 (2006) 1521-1534